Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 42

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 42
---
 patients suffering from other disorders with significant unmet medical needs and limited treatment options. These other potential product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials, and approval by the FDA and/or comparable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products, if approved, will be manufactured or produced economically, successfully commercialized, or widely accepted in the marketplace, or be more effective than other commercially available alternatives. Research programs to identify product candidates require substantial technical, financial, and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:

| • |     | the research methodology used may not be successful in identifying potential product candidates; |

27

| • |     | competitors may develop alternatives that render our product candidate(s) obsolete; |

| • |     | product candidates that we develop may nevertheless be covered by third parties’ patents or other exclusive 
 rights;                                                                                                     |

| • |     | a product candidate may, on further study, be shown to have harmful side effects or other characteristics that 
 indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;             |

| • |     | a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at 
 all; and                                                                                                       |

| • |     | a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party 
 payors.                                                                                                          |

If we are unsuccessful in identifying and developing additional product candidates, our potential for growth and achieving our strategic objectives may be impaired. We may expend our resources to pursue a particular product candidate or indication and forgo the opportunity to capitalize on product candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success. Because we have limited financial and managerial resources, we intend to focus on developing product candidate for specific indications that we identify as most likely to succeed, in terms of both their potential for regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Our